36 results on '"van Laar, Teus"'
Search Results
2. Cerebral topography of vesicular cholinergic transporter changes in neurologically intact adults: A [18F]FEOBV PET study
3. Postural and gait symptoms in de novo Parkinson's disease patients correlate with cholinergic white matter pathology
4. Enhanced arm swing improves Parkinsonian gait with EEG power modulations resembling healthy gait
5. Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study
6. Retinal layers in Parkinson's disease: A meta-analysis of spectral-domain optical coherence tomography studies
7. Accuracy of Intraoperative Computed Tomography in Deep Brain Stimulation—A Prospective Noninferiority Study
8. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial
9. Substituting the Target After Unsatisfactory Outcome of Deep Brain Stimulation in Advanced Parkinson’s Disease: Cases From the NSTAPS Trial and Systematic Review of the Literature
10. Deep Brain Stimulation for Essential Tremor: A Comparison of Targets
11. Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: A retrospective long-term follow-up study
12. Short-latency afferent inhibition as a biomarker of cholinergic degeneration compared to PET imaging in Parkinson's disease
13. Cognitive and psychiatric outcome 3 years after globus pallidus pars interna or subthalamic nucleus deep brain stimulation for Parkinson's disease
14. Unmet needs in Parkinson's disease: New horizons in a changing landscape
15. The need for non-oral therapy in Parkinson's disease; a potential role for apomorphine
16. Understanding the role of the Parkinson's disease nurse specialist in the delivery of apomorphine therapy
17. Parkinson's disease, visual hallucinations and apomorphine: A review of the available evidence
18. Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson's disease patients
19. Functional (psychogenic) movement disorders associated with normal scores in psychological questionnaires: A case control study
20. Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease – Clinical practice recommendations
21. Occupational exposure to solvents, metals and welding fumes and risk of Parkinson's disease
22. Clinical Relevance of Pharmacological and Physiological Data in Intrathecal Baclofen Therapy
23. Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial
24. Early factors for predicting discontinuation to subcutaneous Apomorphine infusion in Parkinson's disease: A prospective analysis of the Thai Apomorphine Registry
25. Attentional and perceptual impairments in Parkinson's disease with visual hallucinations
26. Treatment of subcutaneous nodules after infusion of apomorphine; a biopsy-controlled study comparing 4 frequently used therapies
27. Oscillatory activity and cortical coherence of the nucleus basalis of Meynert in Parkinson's disease dementia
28. Letter to the editor, “Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications”
29. Deep Brain Stimulation in a Dopaminergic Non-responsive Patient With Parkinson's Disease: Case Report and Systematic Review
30. Improved Gait Performance in a Patient With Hereditary Spastic Paraplegia After a Continuous Intrathecal Baclofen Test Infusion and Subsequent Pump Implantation: A Case Report
31. How Many Patients would Benefit from Steering Technology for Deep Brain Stimulation?
32. Effect of pharmacist-led interventions on motor symptoms in Parkinson's patients: A pilot study
33. Effect of pharmacist-led interventions on motor symptoms in Parkinson's patients: A pilot study
34. Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations
35. 1.IS.3. On-going developments in the use of apomorphine in complex Parkinson's disease (Britannia Pharmaceuticals Ltd.)
36. Comparison of two software programs to be used for the calculation of population pharmacokinetic parameters
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.